Applied Therapeutics (APLT) Accumulated Expenses (2023 - 2025)
Historic Accumulated Expenses for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $23.5 million.
- Applied Therapeutics' Accumulated Expenses rose 7416.41% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 7416.41%. This contributed to the annual value of $16.1 million for FY2024, which is 560.64% up from last year.
- Per Applied Therapeutics' latest filing, its Accumulated Expenses stood at $23.5 million for Q3 2025, which was up 7416.41% from $10.7 million recorded in Q2 2025.
- In the past 5 years, Applied Therapeutics' Accumulated Expenses registered a high of $23.5 million during Q3 2025, and its lowest value of $9.5 million during Q1 2025.
- For the 3-year period, Applied Therapeutics' Accumulated Expenses averaged around $14.2 million, with its median value being $14.0 million (2023).
- As far as peak fluctuations go, Applied Therapeutics' Accumulated Expenses crashed by 3574.24% in 2024, and later surged by 7416.41% in 2025.
- Over the past 3 years, Applied Therapeutics' Accumulated Expenses (Quarter) stood at $15.3 million in 2023, then increased by 5.61% to $16.1 million in 2024, then skyrocketed by 45.53% to $23.5 million in 2025.
- Its Accumulated Expenses was $23.5 million in Q3 2025, compared to $10.7 million in Q2 2025 and $9.5 million in Q1 2025.